Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2006 2
2009 1
2010 1
2011 5
2012 2
2014 3
2015 4
2016 5
2018 2
2019 3
2020 5
2021 6
2022 4
2023 4
2024 6
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

52 results

Results by year

Filters applied: . Clear all
Page 1
A randomized trial comparing safety, immunogenicity and efficacy of self-amplifying mRNA and adenovirus-vector COVID-19 vaccines.
Ho NT, Hughes SG, Sekulovich R, Ta VT, Nguyen TV, Van Pham AT, Luong QC, Le Tran LT, Van Luu AT, Nguyen AN, Pham HT, Nguyen VT, Berdieva D, Bugarini R, Liu X, Verhoeven C, Smolenov I, Nguyen XH. Ho NT, et al. Among authors: smolenov i. NPJ Vaccines. 2024 Nov 23;9(1):233. doi: 10.1038/s41541-024-01017-5. NPJ Vaccines. 2024. PMID: 39580505 Free PMC article.
Immunogenicity of a booster dose of a bivalent (Asp614Gly and omicron BA.4/5 variant) self-amplifying mRNA SARS-CoV-2 booster vaccine versus the BNT162b2 omicron BA.4/5 mRNA vaccine: a randomised phase 3 trial.
Okada Y, Kumagai Y, Okura I, Otsuki M, Ishida N, Iwama Y, Minamida T, Yagi Y, Kurosawa T, van Boxmeer J, Zhang Y, Smolenov I, Walson JL. Okada Y, et al. Among authors: smolenov i. Lancet Infect Dis. 2024 Oct 23:S1473-3099(24)00565-6. doi: 10.1016/S1473-3099(24)00565-6. Online ahead of print. Lancet Infect Dis. 2024. PMID: 39461355
Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine: pooled phase 1, 2, 3a and 3b randomized, controlled trials.
Hồ NT, Hughes SG, Ta VT, Phan LT, Đỗ Q, Nguyễn TV, Phạm ATV, Thị Ngọc Đặng M, Nguyễn LV, Trịnh QV, Phạm HN, Chử MV, Nguyễn TT, Lương QC, Tường Lê VT, Nguyễn TV, Trần LT, Thi Van Luu A, Nguyen AN, Nguyen NT, Vu HS, Edelman JM, Parker S, Sullivan B, Sullivan S, Ruan Q, Clemente B, Luk B, Lindert K, Berdieva D, Murphy K, Sekulovich R, Greener B, Smolenov I, Chivukula P, Nguyễn VT, Nguyen XH. Hồ NT, et al. Among authors: smolenov i. Nat Commun. 2024 May 14;15(1):4081. doi: 10.1038/s41467-024-47905-1. Nat Commun. 2024. PMID: 38744844 Free PMC article. Clinical Trial.
SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines.
Roa CC Jr, de Los Reyes MRA, Plennevaux E, Smolenov I, Hu B, Gao F, Ilagan H, Ambrosino D, Siber G, Clemens R, Han HH. Roa CC Jr, et al. Among authors: smolenov i. Hum Vaccin Immunother. 2024 Dec 31;20(1):2301632. doi: 10.1080/21645515.2023.2301632. Epub 2024 Jan 11. Hum Vaccin Immunother. 2024. PMID: 38206168 Free PMC article. Clinical Trial.
Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12-17 year-old adolescents.
Lopez P, Bravo L, Buntinx E, Borja-Tabora C, Velasquez H, Rodriquez EJ, Rodriguez CA, Carlos J, Montellano MEB, Alberto ER, Salvani-Bautista M, Huang Y, Hu B, Li P, Han HH, Baccarini C, Smolenov I. Lopez P, et al. Among authors: smolenov i. Hum Vaccin Immunother. 2023 Dec 31;19(1):2206359. doi: 10.1080/21645515.2023.2206359. Epub 2023 May 25. Hum Vaccin Immunother. 2023. PMID: 37226504 Free PMC article. Clinical Trial.
Six-month safety follow-up of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in adults: A phase 2/3, double-blind, randomized study.
Hosain R, Aquino P, Baccarini C, Smolenov I, Li P, Qin H, Verhoeven C, Hu B, Huang Y, Rubio P; SPECTRA Study Group. Hosain R, et al. Among authors: smolenov i. Vaccine. 2023 Mar 24;41(13):2253-2260. doi: 10.1016/j.vaccine.2023.02.018. Epub 2023 Feb 10. Vaccine. 2023. PMID: 36868877 Free PMC article. Clinical Trial.
Immunogenicity of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in SARS-CoV-2-naïve and exposed individuals in a phase 2/3, double-blind, randomized study.
Buntinx E, Brochado L, Borja-Tabora C, Yu CY, Alberto ER, Montellano MEB, Carlos JC, Toloza LB, Hites M, Siber G, Clemens R, Ambrosino D, Qin H, Chen HL, Han HH, Hu B, Li P, Baccarini C, Smolenov I. Buntinx E, et al. Among authors: smolenov i. Vaccine. 2023 Mar 10;41(11):1875-1884. doi: 10.1016/j.vaccine.2023.02.017. Epub 2023 Feb 9. Vaccine. 2023. PMID: 36781334 Free PMC article. Clinical Trial.
52 results